Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of TG Therapeutics Inc (NASDAQ: TGTX) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of TG Therapeutics Inc (NASDAQ: TGTX) concerning whether a series of statements by TG Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On September 25, 2018, the Company issued a press release announcing “that the independent Data Safety Monitoring Board (DSMB) for the UNITY-CLL Phase 3 trial met to review ongoing data from the study and advised the Company that the interim analysis of Overall Response Rate (ORR) could not be conducted at this time as the data were not sufficiently mature to conduct the analysis.”

On this news, NASDAQ: TGTX fell more than 44% to close at $5.15 per share on September 25, 2018.

Based in New York, New York, and founded in 1993 TG Therapeutics Inc focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States.

If you purchased shares of TG Therapeutics Inc (NASDAQ: TGTX) on or before September 25, 2018, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185